KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to -$929000.0.

  • Aurinia Pharmaceuticals' Other Operating Expenses rose 7968.95% to -$929000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year decrease of 936.86%. This contributed to the annual value of $4.3 million for FY2024, which is 15187.97% up from last year.
  • Aurinia Pharmaceuticals' Other Operating Expenses amounted to -$929000.0 in Q3 2025, which was up 7968.95% from -$9.2 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Other Operating Expenses peaked at $4.5 million during Q4 2024, and registered a low of -$9.2 million during Q2 2025.
  • Moreover, its 5-year median value for Other Operating Expenses was -$55000.0 (2021), whereas its average is -$930894.7.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Other Operating Expenses skyrocketed by 154328.36% in 2021, and later crashed by 328827.59% in 2025.
  • Aurinia Pharmaceuticals' Other Operating Expenses (Quarter) stood at $285000.0 in 2021, then soared by 661.4% to $2.2 million in 2022, then tumbled by 518.16% to -$9.1 million in 2023, then surged by 149.66% to $4.5 million in 2024, then tumbled by 120.62% to -$929000.0 in 2025.
  • Its last three reported values are -$929000.0 in Q3 2025, -$9.2 million for Q2 2025, and -$4.4 million during Q1 2025.